Article
Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
Clinical journal of gastroenterology - 1 Apr 2022
Nakano Mae, Shimada Yoshifumi, Matsumoto Yoshifumi, Saiki Takuro, Zhou Qiliang, Sasaki Kenta, Moriyama Masato, Yoshihara Kosuke, Natsumeda Manabu, Kuriyama Yoko, Takii Yasumasa, Watanabe Gen, Umezu Hajime, Okuda Shujiro, Ikeuchi Takeshi, Wakai Toshifumi, Saijo Yasuo
Abstract excerpt
Neuroendocrine neoplasms of the colon and rectum are colorectal epithelial neoplasms with neuroendocrine differentiation. A platinum regimen used for small cell lung cancer is the currently recommended chemotherapy for gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs), regardless of the organ. The BRAF V600E mutation has been recently reported as a druggable driver mutation in colorectal NECs. In BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.